Hemostemix Inc.
HMTXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.57M
Close$
$-0.01
131.3% downside
Current Fair Value
131.3% downsideOvervalued by 131.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $10.57 Million |
|---|---|
| Enterprise Value | $14.00 Million |
| Earnings per Share | $-0.03 |
| Beta | 0.61 |
| Outstanding Shares | 204,994,910 |
Return
| Return on Equity | 78.43% |
|---|---|
| Return on Assets | -1758.21% |
| Return on Invested Capital | 251.88% |
Valuation & Multiples
| P/E Ratio | -2.02 |
|---|---|
| PEG | -2.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.04 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.25 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | -0.62 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 27, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hemostemix Inc.
12 employees
CEO: Thomas A. Smeenk
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for t...